Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Biotechnology
Corporate & Fiscal
Drug Delivery
Health Products
Hospital Markets
Indication Areas
Medical Devices
Prescription Medicines
R&D
Custom Research
Pharmaceutical Events & Conferences
Contact
Terms & Conditions
Privacy
Home >
Eisai Co. Ltd: PharmaVitae Profile
Market Study
Published: June 2010
Pages: 68
Tables: For full details, please email keithw@cmsinfo.com
From: GBP 3562.50 Buy Now!
Research from: Datamonitor
Sector: Corporate & Fiscal
Introduction
This analysis examines the historical and forecast performance for Eisai in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
*Benchmark Eisai's performance against key rivals in the prescription pharmaceutical sector
*See how the loss of patent protection on Eisai's blockbuster products Aricept and AcipHex/Pariet will impact Rx performance over 2008-14
*Evaluate Eisai's long-term growth potential following the acquisition of US companies Morphotek and MGI Pharma in 2007 and 2008 respectively
This analysis examines the historical and forecast performance for Eisai in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to Purchase
*Benchmark Eisai's performance against key rivals in the prescription pharmaceutical sector
*See how the loss of patent protection on Eisai's blockbuster products Aricept and AcipHex/Pariet will impact Rx performance over 2008-14
*Evaluate Eisai's long-term growth potential following the acquisition of US companies Morphotek and MGI Pharma in 2007 and 2008 respectively